And...that’s a wrap for #ADPD2026!✨
What an unforgettable few days in Copenhagen - filled with inspiring science, meaningful connections, and incredible moments shared across the global AD/PD™ community. 🧠🌍
Thank you to everyone who joined us - onsite and online - for being part of this journey.
🇪🇸 We can’t wait to see you next year in Barcelona for AD/PD™ 2027!
#Neuroscience#Alzheimers#Parkinsons#NeurodegenerativeDiseases#ADPDCommunity#SeeYouInBarcelona
The AD/PD™ Journey Continues in Barcelona!
From scientific exchange to inspiring conversations, see what made last year’s AD/PD™ Congress in Copenhagen so memorable.
Watch the highlights and get ready to experience AD/PD™ in Barcelona!
youtube.com/watch?v=Qqu4v2eR…#ADPD2027#Alzheimers#Parkinsons
Forum Discussions: Where the audience joins the conversation.
Eight Forum Discussions will bring together experts from neuroscience, clinical practice, and industry. Each session will open with brief participant remarks, followed by audience Q&A and media coverage highlighting progress in the field.
• Global leadership forum: Moonshots & milestones: Who will own the future of neurodegeneration?
• Biomarkers that decide: Are we ready to treat before symptoms?
• AI → Impact: Can data-driven biology deliver real disease-modifying therapies?
• Optimizing therapy: Promising combination strategies in AD and PD
• Rewiring the failing brain: Can circuit-based therapies deliver the next generation of CNS drugs?
• Precision neurology: Matching the right drug to the right patient - from biomarkers to clinical reality
• Biomarkers and disease modification in PD: Targeting alpha-synuclein, LRRK2 and GBA.
• Microglia in command: Reprogramming the brain–immune axis - breakthroughs, targets, and risks
Explore more: adpd.kenes.com/forum-discuss…#ADPD2027#Alzheimers#Parkinsons
📰 Hello Lipizone, Unit of 3D Map of Brain Lipids
"Calling all lipid enthusiasts! Scientists have put together a three-dimensional map of where these molecules reside throughout the entire mouse brain. Using high-tech mass-spec imaging, researchers led by Giovanni D’Angelo and Gioele La Manno at the Swiss Federal Institute of Technology - Lausanne, Switzerland, identified 539 distinct clusters of lipids, which they call “lipizones.” The organization largely aligns with known anatomical regions. Some lipizones correspond to certain cell types, while others trace neural connections between distant areas of the brain. Pregnancy remodeled lipizones in the ventricles, choroid plexus, cortex, and white matter."
The study appeared in Nature on September 23.
Continue reading: alzforum.org/news/research-n…
The AD/PD™ 2027 Scientific Program brings together speakers from around the world to discuss Alzheimer’s, Parkinson’s, and related disorders. From the molecular signatures of brain function to GBA-1 focused trials in Parkinson’s, the sessions cover both laboratory science and clinical research.
Here is a first look at some of the topics and speakers:
• Molecular Signatures of Brain Function | Tony Wyss-Coray, United States
• GBA-1 Focused Trials in Parkinson’s | Roy N. Alcalay, Israel
• Symptomatic and Disease Modifying Therapy in Parkinson’s Disease | Fabrizio Stocchi, Italy
• Molecular Signaling Pathways Governing Microglial Senescence In Neurodegeneration | Peter St. George-Hyslop, Canada
• Glial Presenilin Function in the Aging Brain | Jie Shen, United States
There’s a lot more in the full program.
Take a look and start planning: adpd.kenes.com/scientific-pr…#ADPD2027#Alzheimers#Parkinsons
⏱️ LAST CALL!
Join us tomorrow for a 60-minute live webinar exploring Taudia’s validated 5-plex laboratory-developed test (LDT) and its applications in clinical research.
📅 Tomorrow, 12 November 2026 at 16:00 CET
👉 REGISTER NOW: bit.ly/4jwOD24
Discover the science behind multi-analyte testing, explore Taudia’s SPLASH technology, and gain insights into assay validation and the role of 5-plex testing in AD research.
🚀 SECURE YOUR SPOT AND JOIN US LIVE TOMORROW!
This educational webinar is supported by #Taudia.
#AlzheimersDisease#Biomarkers#ClinicalResearch#Neuroscience#MedicalEducation#ADPDEducation#ADPDonUNLOK
One month left to register and save up to €150!
Register for AD/PD™ 2027 by December 9, 2026, to benefit from the early registration rates.
From 16–20 March 2027, Barcelona will bring together researchers and clinicians for five days of new science, open debate, and connections that continue well beyond the conference.
Register today: adpd.kenes.com/register/#ADPD2027#AlzheimersResearch#ParkinsonsResearch#Neuroscience#Neurodegeneration
MEET THE EXPERTS!
Join three experts bringing complementary perspectives in assay development, clinical testing, and life sciences innovation:
👨⚕️ Paul Childress, PhD - Principal Investigator at Quantigen, with extensive experience in assay development, validation, and molecular and protein-based testing.
👨⚕️ Doug Rains - Chief Scientific Officer of Versiti Clinical Trials Solutions, with a background spanning oncology research, genetic testing, and biotechnology.
👨⚕️ Christopher Ng - Director of Operations at Taudia, specializing in proteomics, genomics, and bringing innovative life science products to clinical research.
Together, they’ll explore the science behind the validated AD 5-plex assay, Taudia’s SPLASH technology, and the role of multi-biomarker testing in clinical research.
📅 12 NOVEMBER AT 16:00 CET
👉 REGISTER NOW: bit.ly/4yun652
This educational webinar is supported by #Taudia.
#AlzheimersResearch#ClinicalTrials#AlzheimersDisease#Biomarkers#ClinicalResearch#Neuroscience#MedicalEducation#ADPDEducation#ADPDonUNLOK
🤝 Put your startup in front of specialists working in Alzheimer’s, Parkinson’s and related disorders.
The #ADPD2027 Startup Hub is an opportunity to share what you are building, gain expert perspectives and open the door to new opportunities.
🔗 Reserve your tabletop: bit.ly/4kqDNsD#Alzheimers#Parkinsons
"Having been in the field since 1988, it is quite extraordinary where we are today, and AD/PD has played a seminal role and will continue to do so." - Rhoda Au, Boston University, on AD/PD™ 2026. ✨
In Barcelona, Rhoda co-moderates the forum "AI → Impact: Can data-driven biology deliver real disease-modifying therapies?" with Randall Bateman.
🔗Join the conversation, 16–20 March 2027: adpd.kenes.com/#ADPD2027#AlzheimersResearch#AI#Neuroscience
Why do so many researchers return to AD/PD™ every year?
✔️ A high-level scientific program focused on the latest research, with emphasis on overlaps between Alzheimer's, Parkinson's, and related disorders
✔️ A multidisciplinary mix of clinical investigators and basic scientists, established leaders and young talent
✔️ An atmosphere designed for interaction, exchange of ideas, and networking
Plenary speakers in Barcelona include Randall Bateman, Henrik Zetterberg, Brit Mollenhauer, Bradley Hyman, Rosa Rademakers, Costantino Iadecola, and Beth Stevens. ✨
📆Join us in Barcelona or online, 16–20 March 2027
Register: adpd.kenes.com/register/#ADPD2027#AlzheimersResearch#ParkinsonsResearch#Neuroscience
🔬 The specialists deciding what moves forward in Alzheimer’s, Parkinson’s, and related disorders are at #ADPD2027.
Early-stage companies belong in that room. Get feedback and contacts that shape what your technology becomes.
🔗 Join the Startup Hub: bit.ly/4kqDNsD#Alzheimers#Parkinsons
"It is clear to me that we have entered a new and very positive phase, and that the speed of discovery and progress is higher than ever with quite innovative approaches." ✨
Henrik Zetterberg, University of Gothenburg, reflecting on AD/PD™ 2026 in Copenhagen.
In Barcelona, Henrik returns as a plenary speaker on fluid biomarkers for tau pathophysiology in Alzheimer's disease.
🔗Join us, save your seat today: adpd.kenes.com/#ADPD2027#AlzheimersResearch#Biomarkers#Neuroscience
🧠 THE SCIENCE BEHIND AD 5-PLEX TESTING
Can five biomarkers provide a broader picture of Alzheimer's disease than a single biomarker?
Join Paul Childress, PhD, Doug Rains, and Christopher Ng for an expert-led discussion on multi-analyte blood-based testing, assay validation, and clinical research applications.
📅 Thursday, 12 November 2026
⏰ 16:00 CET
👉 REGISTER NOW: bit.ly/4yun652
This educational webinar is supported by #Taudia.
#AlzheimersDisease#Biomarkers#ClinicalResearch#Neuroscience#MedicalEducation#ADPDEducation#ADPDonUNLOK
Preparing a late-breaking abstract for #ADPD2027? A quick checklist before you submit:
✅ Data must be unpublished and not previously presented
✅ Title: max. 20 words, in UPPER CASE
✅ Abstract text: max. 280 words, structured as Objectives, Methods, Results, Conclusions
✅ The presenting author must be listed as first author
✅ Choose a Theme, Topic and Sub-Topic
✅ You're not submitted until you receive the confirmation email
AD/PD™ has no embargo policy, so you're free to share your work within your networks.
📅 Deadline: 18 November 2026, midnight CET
👉 adpd.kenes.com/abstract-subm…#ADPD2027#AlzheimersResearch#ParkinsonsResearch#Neuroscience
Can't travel to Barcelona? You can still be part of AD/PD™ 2027.
As a hybrid conference, AD/PD™ 2027 lets you join live sessions online, alongside the in-person meeting in Barcelona, 16–20 March 2027.
With the Gold Track, you also keep access to session recordings, abstracts, e-posters, and the conference digital library for 6 months after the meeting.
📆 Early rates apply until 9 December 2026.
👉 adpd.kenes.com/register/#ADPD2027#AlzheimersResearch#ParkinsonsResearch#Neuroscience